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Abstract: Melatonin acts classically through the widely expressed G protein-coupled membrane receptors MT1 and MT2, respectively.
The functional role of the MT receptors is not fully clear with multiple effects, such as effects on the circadian, reproductive, immune,
cardiovascular, and intestinal systems, being suggested. In addition to receptor-mediated effects, melatonin also acts as a potent
antioxidant and it is quite evident that melatonin and its metabolites efficiently reduce oxidative damage to proteins, lipids, and DNA
and also exert protective effects on mitochondria. The potent antioxidant activity of melatonin stems from various complex mechanisms,
including direct scavenging of radicals, stimulation of antioxidant enzymes, and maintenance of mitochondrial homeostasis. However,
about a dozen experimental studies also suggest that melatonin can exert prooxidant effects under certain circumstances. Involvement
of calmodulin and the mitochondrial respiratory chain may be potential targets for the prooxidant effects of melatonin. This review
briefly summarizes the physiobiochemistry of melatonin, including its antioxidative functions, and summarizes and discusses studies
showing prooxidant effects of this hormone.
Key words: Melatonin, physiology, free radicals, mitochondria, antioxidative effects, prooxidant effects

1. Introduction
Melatonin, chemically N-acetyl-5-methoxytryptamine,
was primarily isolated from bovine pineal glands and
its structure was first identified in 1958 (Lerner et al.,
1958). This indolamine was later discovered to be also
present or synthesized in extrapineal tissues such as the
retina, gastrointestinal tract, Harderian gland, testes,
and lymphocytes (Reiter et al., 2013). Due to the fact
that melatonin possesses hydrophilic and lipophilic
characteristics, its lipophilic ability enables it to penetrate
all biological membranes, including the blood–brain
barrier (Reiter et al., 1997). Generally, melatonin
derives from the essential amino acid tryptophan by a
multistep enzymatic reaction chain, including tryptophan
5-hydroxylation,
decarboxylation,
N-acetylation,
and O-methylation. Furthermore, melatonin can
be synthesized via O-methylation of serotonin and
subsequent N-acetylation of 5-methoxytryptamine, or by
O-methylation of tryptophan, followed by decarboxylation
and N-acetylation (Hardeland et al., 1993). From a
functional perspective, melatonin is characterized as
a hormone involved in the regulation of the circadian
rhythm of several biological functions and it also plays
an important role in immunoregulation, reproduction,
sleep, and inflammatory responses (Hardeland and
* Correspondence: cem.ekmekcioglu@meduniwien.ac.at
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Fuhrberg, 1996; Reiter et al., 2000). MT1 and MT2 are two
well-characterized G protein-coupled plasma membrane
melatonin receptors, which are activated by melatonin
and regulate multiple cellular and physiological functions,
including neuronal activity, arterial vasoconstriction,
cell proliferation, immune responses, reproduction,
and metabolic functions (Stankov and Reiter, 1990;
Dubocovich and Markowska, 2005; Ekmekçioğlu, 2006,
2014). In addition, melatonin has high-affinity binding
for nuclear receptors ROR/RZR, which operate as
transcriptional activators, and it also interacts with other
intracellular proteins, like quinone reductase-2 (or MT3)
and calmodulin (Reppert et al., 1994; Wiesenberg et al.,
1998). For the regulation of gene expression, it has been
proposed that ROR/RZR work in cooperation with the
plasma membrane receptors MT1/MT2 (Carrillo-Vico
et al., 2005). Regarding the regulation of the cellular
redox status, melatonin possibly interacts with quinone
reductase, even though the detailed role of this interaction
remains poorly understood (Tan et al., 2007).
Melatonin and calmodulin possess low-affinity
interaction, which may relate to their antioxidant actions,
as well as other signaling processes (Luchetti et al., 2010).
Various studies describe melatonin and its derivatives as
broad-spectrum antioxidants, related to their ability to
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act as potent free radical scavengers (Reiter et al., 2002;
Tan et al., 2007). While the regulation of gene expression
may imply an interaction of melatonin with its common
receptors MT1/MT2 and possibly also RZR/ROR, the
direct radical scavenging actions of melatonin are usually
receptor-independent. In general, it is well established that
melatonin and its metabolites reduce oxidative damage to
proteins, lipids, and DNA. They also play a protective role
in mitochondria, by preventing them from undergoing
oxidative damage. Therefore, melatonin improves or
preserves ATP production, mitochondrial respiration,
membrane potential, and permeability transition and
consequently prevents electron leakage and reactive
oxygen species (ROS) production (Zhang and Zhang,
2014). In addition, studies from the last years suggested
that melatonin also exerts prooxidant effects under certain
circumstances (Zhang and Zhang, 2014). This brief review
will especially focus on this topic.
2. Reactive oxygen species and oxidative stress
ROS result as natural byproducts of the normal metabolism
of oxygen and are considered as highly reactive molecules
because of their presence of unpaired electrons (Rezaie et
al., 2007). In this regard free radicals are small, diffusible,
and reactive molecules that participate in chain reactions,
in which even a single free radical initiation event could
distribute damage to multiple molecules (Jones, 2008).
Vital tissues consist of complex antioxidative defense
systems to avoid the destructive effects implicated by ROS
(Table 1). A high ROS burden leads to oxidative stress,
which is defined as a marked imbalance between the
production of ROS and their elimination by antioxidants
(Rezaie et al., 2007). In general, macromolecular damage

is typically observed in the broader sense of oxidative
mechanisms, linked to free radicals (Jones, 2008).
The toxic species that could be responsible for diseases
and aging are in general categorized in two groups: ROS
and reactive nitrogen species (RNS). Singlet oxygen (O2•),
superoxide (O2•-), hydrogen peroxide (H2O2), and the
hydroxyl radical (OH•) belong to ROS (Halliwell, 2006),
whereby the hydroxyl radical is responsible for the largest
amount of damage in living cells (Finkel and Holbrook,
2000). On the other hand, nitric oxide and especially its
product peroxynitrite are included in the RNS category
(Packer et al., 1996).
Free radicals are produced during normal
mitochondrial metabolism and also by a variety of
cytosolic enzyme systems, like lipoxygenase, NADPHoxidase, and cytochrome P450 (Finkel and Holbrook,
2000). The respiratory chain is, so far as we know,
a powerful source of ROS, and there are two major
regions where ROS are produced, one being complex I
(NADPH coenzyme Q reductase) and the other complex
III (ubiquinol cytochrome c reductase) (Fridovich,
1986; Cross and Jones, 1991). Due to the exposure to
highly concentrated ROS, mitochondrial structures are
particularly predisposed to free radical attack (Valls et al.,
1994). Here, lipid peroxidation, protein oxidation, and
mitochondrial DNA mutations can be consequences of the
oxidative damage to mitochondrial components (Richter
et al., 1988; Stadtman, 1992; Ernster, 1993).
Furthermore, free radicals can have deleterious
consequences at the cellular level, like cell death or tumor
genesis. Free radicals enhance activation of caspases, cell
cycle control protein p53, cytochrome c release from
mitochondria, and other apoptotic signaling proteins

Table 1. Major endo- and exogenous antioxidants.
Endogenous antioxidants
Enzymatic antioxidants:
-Superoxide dismutase (SOD) – dependent on manganese, zinc, and copper
-Catalase (CAT) – dependent on iron
-Glutathione peroxidase (GPx) – dependent on selenium
-Glutathione reductase (GR)
-Thioredoxin reductase (TrxR) – dependent on selenium
Nonenzymatic antioxidants:
-Glutathione (GSH) -Melatonin
-Uric acid		
-Coenzyme Q
-Lipoic acid
-Transferrin
-Albumin 		
-Lactoferrin
-Bilirubin 		
-Ceruloplasmin
-Nicotinamide adenine dinucleotide phosphate (NADPH)

Exogenous antioxidants
Mainly dietary antioxidants from plant based healthy foods:
-Vitamins: vitamin A, C, E
-Trace elements: zinc, selenium (as parts of enzymes)
-Carotenoids: β-carotene, lycopene, lutein, zeaxanthin
-Phenolic acids: chlorogenic acids, gallic acid, caffeic acid, and others
-Flavonols: quercetin, kaempferol, myricetin
-Flavanols: proanthocyanidins, catechins
-Anthocyanidins: cyanidin, pelargonidin
-Isoflavones: genistein, daidzein, glycitein

Adapted from Bouayed and Bohn (2010) and Barceló and Barbé (2005).
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dependent or independent of mitochondria (Chandra et
al., 2000; Sinha et al., 2013). They also play an important
role in the initiation and progression of tumors and are
additionally related to the induction of cellular senescence
(Dreher and Junod, 1996; Lu and Finkel, 2008). Several
exogenous factors can be responsible for the generation
of ROS, like ultraviolet radiation, cigarette smoking,
alcohol, ischemia-reperfusion injury, chronic infections,
and inflammatory disorders (Bhattacharyya et al., 2014).
Cigarette tar in particular can produce large amounts of
H2O2 (Nakayama et al., 1989). For this reason, smoking
can promote lipid peroxidation of cellular membrane
lipids, thus stimulating atherosclerosis and endothelial
dysfunction and increasing the risk for lung cancer and
cardiovascular diseases (Frei et al., 1991; Santanam et al.
1997; Ambrose and Barua, 2004).
3. Antioxidative effects of melatonin
The potent antioxidant activity of melatonin derives from
various complex mechanisms, including direct scavenging
of radicals, suppression of prooxidant enzymes, stimulation
of antioxidant enzymes, and maintenance of mitochondrial
homeostasis. Generally speaking, melatonin provides
protective cellular effects, especially for mitochondria,
and it prevents the damage of proteins, lipids, and DNA
(Zhang and Zhang, 2014). In vivo experiments pointed
out that melatonin increases gene expression of multiple
antioxidative genes in neuronal tissues, including those
of CuZnSOD, MnSOD, GPx, catalase, and glutathione
reductase (Kotler et al., 1998; Esparza et al., 2005; Gomez
et al., 2005).
There is also evidence that melatonin protects skin from
UV injury by enhancing the expression of SOD, catalase,
and GPx (Fischer et al., 2013). Some experimental models of
tissue damage demonstrate that melatonin acts protectively
by reducing oxidative stress and lipid peroxidation (Pieri et
al., 1995; Reiter et al., 1998). Furthermore, melatonin exerts
anticancer activities through either cytostatic mechanisms
or cytotoxic actions by inhibiting cell proliferation and/or
reducing viability in several cancer cell lines, including
rat pancreatic tumor cells (Gonzalez et al., 2011), human
hepatocellular carcinoma cells (Ordoñez et al., 2014),
human B-lymphoma cells (Trubiani et al., 2005), human
myeloid HL-60 leukemia cells (Rubio et al., 2007), and
human neuroblastoma cancer cells (Garcia-Santos et al.,
2006).
In addition, melatonin helps to maintain the integrity
of the mitochondrial membrane and interacts with the
mitochondrial electron transport chain complexes I and
IV. For this reason, it promotes electron flux under basal
conditions and increases ATP production (Martin et al.,
2000, 2002). Melatonin is also able to limit the decline
of intramitochondrial glutathione, and related to this it
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improves ATP production, as well as the electron transport
chain activity, by directly detoxifying ROS/RNS. Due to
these capabilities, melatonin may protect against ischemiareperfusion-induced cardiac damage and mitochondrial
dysfunction in sepsis (Lopez et al., 2006; Petrosillo et al.,
2006).
However, the mechanisms implicated in the regulation
of antioxidant enzymes by melatonin in vivo are not
precisely established. It is generally agreed that in cultured
cells the stimulation of antioxidant enzyme gene expression
by melatonin occurs at low to high nanomolar levels (Tan
et al., 2014).
Moreover, it was demonstrated that the metabolites
of melatonin also possess antioxidant abilities.
Melatonin is metabolized through chemical or
enzymatic reactions, leading to formation of AMK (N1acetyl-5-methoxykynuramine), AFMK (N(1)-acetylN(2)-formyl-5-methoxykynuramine),
and
3-OHM
(3-hydroxymelatonin), which have important biological
significance (Reiter et al., 2007; Tan et al., 2007; Galano et
al., 2013). In particular, 3-OHM was observed to be a more
potent antioxidant against OH• and hydroperoxyl (HO2•)
radicals as compared to melatonin or its other metabolites
(Galano et al., 2014; Tan et al., 2014). In addition, it has
been suggested that 3-OHM protects mitochondria against
oxidative damage, because it effectively prevents oxidative
degradation of cytochrome c by H2O2 (Tan et al., 2014). It
was also reported that AFMK reduces lipid peroxidation
and oxidative DNA damage and that AMK has a major
capacity to scavenge ROS (Tan et al., 2001; Ressmeyer
et al., 2003). Furthermore, AMK reduces intracellular
NO levels by inhibiting NOS activity in the cytosol and
in mitochondria (Leon et al., 2006), and both AMK and
AFMK exhibit antiinflammatory and immunoregulatory
activities (Radogna et al., 2010; Mauriz et al., 2013).
4. Prooxidant actions of melatonin
So far, melatonin has been well known for its ability to act
as an antioxidant, and the vast majority of studies have
concentrated on analyzing its role as a scavenger of ROS.
Nevertheless, recent studies were also able to demonstrate
that melatonin can act as a prooxidant under certain
conditions (Zhang and Zhang, 2014) (summarized in
Table 2).
In 1999 Medina-Navarro et al. tested the antioxidant
activity of melatonin in vitro on lipids and erythrocyte
membranes against singlet oxygen, as compared with
ascorbate and beta-carotene. They showed that at a
concentration of 0.5 mM melatonin increased lipid
peroxidation of cell membranes, and after 120 min the
hydroperoxide concentration was about 5 times greater
(35.4 mM) than the maximum concentration reached by
the sample in the absence of antioxidants (7.2 mM). In
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Table 2. Summary of studies showing prooxidant effects of melatonin.
Effect

Melatonin
concentration

Incubation time
with melatonin

Cell type

Reference

Lipid, protein oxidation

0.2–0.6 mM

120 min

Erythrocyte membranes

Medina-Navarro et al., 1999

Cell viability↓
GSH↓, ROS↑

0.1–10 µM
1–10 mM

96 h
15 min

HepG2

Osseni et al., 2000

ROS↑, Fas-induced apoptosis↑

0.01–1 mM

30–360 min

Jurkat

Wolfler et al., 2001

Redox active iron↑, hemeoxygenase-I↑

1 mM

5h

Mouse brain slice

Clapp-Lilly et al., 2001

Cytotoxicity↑, ROS↑

1 mM

48 h

CMK, Jurkat, MOLT-4

Büyükavcı et al., 2006

ROS↑, GSH↓

1 mM

2 and 6 h

U937

Albertini et al., 2006

ROS↑, 5-LOX↑, PLA2↑,
arachidonic acid↑,

1 mM

1 min to ~5–6 h

U937

Radogna et al., 2009a;
Radogna et al., 2009b

NF-κB↑

1 mM

Up to 5 h

U937

Cristofanon et al., 2009

ROS↑, viability↓,
caspase activity↑

1 mM

1–24 h

HL-60

Bejarano et al., 2011

ROS↑

2–25 µM

~20 min

Isolated renal mitochondria

Zhang et al., 2011

ROS↑

2.5–50 µM

~20 min

Human kidney mesangial cells
Zhang et al., 2011
and mitochondria

ROS↑, intracellular calcium↑,
apoptosis↑

20–100 µM

*

Human platelets

Girish et al., 2013

Ca2+ induced mPTP opening↑,
nitrites↑, mitochondria ETC↓,
parasite toxicity↑

25–50 nM

Leishmania infantum

Elmahallawy et al., 2014

72 h

*: Not evident from the publication.
GSH = Glutathione, ROS = reactive oxygen species, CMK = human megakaryoblastic cell line, MOLT-4 = human lymphoblastoid leukemia cell line,
5-LOX = 5-lipoxygenase, PLA2 = phospholipase A2, NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells, mPTP = mitochondrial
permeability transition pore, ETC = electron transport chain.

addition, application of melatonin in the range of 0.2 to
0.6 mM induced protein oxidation (Medina-Navarro et al.,
1999). This was probably the first evidence that melatonin
may act as a prooxidant under certain circumstances
and further investigations in in vitro cellular systems
succeeded.
One of these studies in human leukemic Jurkat cells
showed a concentration- and time-dependent increase of
intracellular ROS generation and Fas-induced apoptosis
by melatonin at concentrations between 10 and 1000
µM, whereas no significant ROS generation at melatonin
concentrations of lower than 10 µM was detected (Wolfler
et al., 2001).
Osseni et al. observed in vitro that the cell viability in
the human liver cell line HepG2 significantly decreased

at melatonin concentrations of 0.1–10 µM after 96 h of
incubation time. In contrast, at a shorter incubation time
of 24 h, antioxidative effects of melatonin were detected
with increased intracellular GSH levels and improvement
of cell viability. High melatonin concentrations from
1 to 10 mM, however, lead to GSH depletion (Osseni
et al., 2000). Another study by Clapp-Lilly et al. in an
organotypic slice culture model of Alzheimer disease
showed that 1 mM melatonin increased markers of
oxidative stress, such as hem-oxygenase-1, as well as
redox active iron, while lower concentrations of melatonin
below 100 µM resulted in a reduction of oxidative stress
(Clapp-Lilly et al., 2001). In addition, Büyükavcı et al.
described that higher concentrations of melatonin showed
moderate cytotoxic effects in CMK, Jurkat, and MOLT-
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4 cells, which were, however, associated with significant
ROS production (Büyükavcı et al., 2006). Regarding the
human promyelocytic leukemia cell line HL-60, melatonin
induced a significant increase of ROS at a concentration of
1 mM after 1–24 h of incubation. The same concentration
increased the activity of caspase-9 and caspase-3, which may
be related to its prooxidant effects (Bejarano et al., 2011).
Cristofanon et al. described that melatonin can induce
NF-κB activation in U937 cells and suggested a possible
involvement for ROS induced by melatonin (Cristofanon
et al., 2009). In contrast to cancer cells, melatonin did not
induce cytotoxicity in noncancer cells, including human
umbilical vein endothelial cells (Cui et al., 2012), primary
hepatocytes (Kojima et al., 1997), neuronal stem cells (Fu
et al., 2011), and HT22, a mouse hippocampal cell line
(Rodriguez et al., 2013). A further study reported that in
human platelets, melatonin considerably increased the
generation of intracellular ROS and Ca2+, stimulating
mitochondrial membrane depolarization, cytochrome c
release, caspase activation, protein phosphorylation, and
phosphatidylserine externalization (Girish et al., 2013).
Regarding the incubation time, several studies noted
a significant increase of ROS from several minutes to 48 h
after the addition of melatonin. It has been, for example,
discovered that ROS production in U937 cells increased
after 2 and 6 h (Albertini et al., 2006), whereas CMK cells,
Jurkat cells, and MOLT-4 cells showed an increase in ROS
production after 48 h. Therefore it is suggested that the
modulation of ROS production is also cell type-dependent.
(Büyükavcı et al., 2006) (Table 2).
Furthermore, one study in HepG2 cells demonstrated
that relatively lower concentrations of melatonin (0.1–10
µM) showed antioxidant effects within 24 h and became
prooxidant after 96 h (Osseni et al., 2000). Generally,
it is important to mention that the prooxidant effects of
melatonin have been only reported in in vitro cell culture
systems, primarily in cancer cells, and therefore could not
be generalized to other cells and systems. Moreover, as
was described in the studies above, the evidence suggests
that the prooxidant action of melatonin is dependent on
concentration, cell type, and incubation time.
5. Potential mechanisms involved in the prooxidant
effects of melatonin
One important mechanism through which melatonin
may promote ROS generation might involve calmodulinmediated PLA2 activation, leading to 5-LOX-mediated
ROS production (Radogna et al., 2009b). A recent
study showed that the calmodulin-specific inhibitor
chlorpromazine inhibits ROS production by melatonin
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in U937 cells. In addition, chlorpromazine prevented
the interaction of melatonin with calmodulin, suggesting
that the weak interaction between calmodulin and
melatonin may be involved in the generation of ROS by
pharmacological concentrations of melatonin (Radogna
et al., 2009b). Furthermore, Anton-Tay et al. observed
that, at physiological concentrations (1 nM), melatonin
modulates the subcellular localization of calmodulin
in MDCK (Madin-Darby canine kidney) cells (AntonTay et al., 1998). Moreover, Sarti et al. noted that within
a few hours melatonin causes a transient increase of the
expression of neuronal nNOS, which leads to an elevated
RNS production in mitochondria. The rise of nNOS
causes a mild reduction in oxidative phosphorylation
efficiency, paralleled by a depression of the mitochondrial
membrane potential and a shift of glycolysis. Interestingly,
the induction of nNOS by melatonin was observed only at
a physiological level of 1 nM and not at 10 or 100 nM of
melatonin (Sarti et al., 2013).
Generation of ROS is probably not dependent on
the plasma membrane MT1/MT2 receptors, because,
for example, the receptor antagonist luzindole does not
block melatonin-mediated ROS generation. Furthermore,
ROS are not stimulated by a set of MT1/MT2 melatonin
analogues (Radogna et al., 2009a). The mitochondrial
complex III may be a potential site for melatonin-induced
ROS generation in cultured primary human mesangial cells
and in mice kidney mitochondria (Zhang H et al., 2011;
Zhang HM et al., 2011). However, it is not clear whether
melatonin directly interacts with the mitochondrial
complex III to increase ROS generation.
6. Conclusions
Related to experimental studies that were primarily conducted in different cell lines, it can be assumed that melatonin can also act as a prooxidant under certain circumstances. The relevance of this finding is unclear; both beneficial or harmful effects may apply. Potential beneficial
effects may include antiparasitic or anticancer actions. On
the other hand, long-term supplementation of melatonin
may possibly also dose-dependently exert side effects,
like in this case generation of free radicals. Experimental
studies showed that antioxidants may also act as prooxidants under certain conditions (Bergstrom et al., 2012),
and epidemiological studies in the last years suggest that
long-term supplementation with antioxidants like vitamin
E may have detrimental effects on health (Bjelakovic et al.,
2013). Little is known about the side effects of melatonin.
Therefore, clinical studies addressing this issue are needed
to estimate potential risks.
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